Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029061 | 0.97 | GRM5 (0.34) | GRM5MAPK14PIM1PIM3 | |
| SCHEMBL16603455 | 0.94 | KDM4E (0.37) | KDM4EATML3MBTL1NPY5RGRM5 | |
| SCHEMBL16606295 | 0.93 | MAPK14 (0.33) | NPY5RGRM5MAPK14PIM1PIM3 | |
| SCHEMBL17264917 | 0.93 | MAPK14 (0.33) | NPY5RGRM5MAPK14PIM1PIM3 | |
| SCHEMBL5031126 | 0.93 | MAPK14 (0.34) | NPY5RGRM5MAPK14PIM1PIM3 | |
| SCHEMBL12396561 | 0.93 | NPC1 (0.34) | NPY5RGRM5MAPK14PIM1PIM3 | |
| SCHEMBL16451564 | 0.93 | GRM5 (0.36) | GRM5MAPK14PIM1PIM3 | |
| SCHEMBL16603453 | 0.93 | GRM5 (0.36) | GRM5MAPK14PIM1PIM3 | |
| SCHEMBL21365316 | 0.93 | NPC1 (0.34) | NPY5RGRM5MAPK14PIM1PIM3 | |
| SCHEMBL5028434 | 0.92 | ALOX5 (0.35) | GRM5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862739-B2 | Metal complexes, comprising carbene ligands having an O-substituted non-cyclometalated aryl group and their use in organic light emitting diodes | UDC IRELAND LIMITED (IE) | 2018-01-09 | — | — | US | disclosed |
| US-20170183367-A1 | Metal Complexes, Comprising Carbene Ligands Having an O-Substituted Non-Cyclometalated Aryl Group and Their Use in Organic Light Emitting Diodes | UDC IRELAND LIMITED (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183367-A1 | Metal Complexes, Comprising Carbene Ligands Having an O-Substituted Non-Cyclometalated Aryl Group and Their Use in Organic Light Emitting Diodes | UDC IRELAND LIMITED (IE) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183367-A1 | Metal Complexes, Comprising Carbene Ligands Having an O-Substituted Non-Cyclometalated Aryl Group and Their Use in Organic Light Emitting Diodes | ICOSLG, CD40LG, OCIAD1 | KDM4E 3918/4885ATM 3309/4885L3MBTL1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.